Choose a language and wait for the translated text.
Shots:
Adcendo has reported initial data from the ongoing P-I (ADCElerate1) trial evaluating ADCE-D01 (uPARAP-targeting ADC) in 47 previously treated patients with advanced soft tissue sarcoma (STS), presented as a late-breaking oral presentation at ENA 2026
Among 27 response-evaluable patients across 12 STS subtypes receiving ADCE-D01 Q2W, ORR was 30% (8 PRs; 5 confirmed) & DCR was 85%; at a median follow-up of 3.4mos., all responses were ongoing & 81% remained on treatment
On the Q2W schedule, side effects led to dose reduction in 10% of patients with no discontinuations; MTD has not been reached. ADCE-D01 holds the US FDA’s Fast Track & Orphan Drug designations for STS
Ref: PR Newswire | Image: Adcendo | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Adcendo Reports P-I (ADCElerate1) Data of ADCE-D01 for Advanced Soft Tissue Sarcoma at ENA 2026 appeared first on PharmaShots.